- Home
- GXAI vs TXMD Comparison
GXAI vs TXMD Comparison
Compare GXAI & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- TXMD
- Stock Information
- Founded
- GXAI 2021
- TXMD 2008
- Country
- GXAI United States
- TXMD United States
- Employees
- GXAI N/A
- TXMD N/A
- Industry
- GXAI
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- TXMD Health Care
- Exchange
- GXAI Nasdaq
- TXMD Nasdaq
- Market Cap
- GXAI 11.3M
- TXMD 12.8M
- IPO Year
- GXAI 2023
- TXMD N/A
- Fundamental
- Price
- GXAI $1.41
- TXMD $1.30
- Analyst Decision
- GXAI
- TXMD
- Analyst Count
- GXAI 0
- TXMD 0
- Target Price
- GXAI N/A
- TXMD N/A
- AVG Volume (30 Days)
- GXAI 565.3K
- TXMD 738.0K
- Earning Date
- GXAI 03-26-2025
- TXMD 03-28-2025
- Dividend Yield
- GXAI N/A
- TXMD N/A
- EPS Growth
- GXAI N/A
- TXMD N/A
- EPS
- GXAI N/A
- TXMD N/A
- Revenue
- GXAI $2,979.00
- TXMD $1,596,000.00
- Revenue This Year
- GXAI N/A
- TXMD $605.07
- Revenue Next Year
- GXAI N/A
- TXMD $1.11
- P/E Ratio
- GXAI N/A
- TXMD N/A
- Revenue Growth
- GXAI N/A
- TXMD N/A
- 52 Week Low
- GXAI $1.01
- TXMD $0.70
- 52 Week High
- GXAI $16.27
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- GXAI 39.78
- TXMD 68.51
- Support Level
- GXAI $1.41
- TXMD $0.95
- Resistance Level
- GXAI $2.00
- TXMD $1.08
- Average True Range (ATR)
- GXAI 0.17
- TXMD 0.09
- MACD
- GXAI 0.03
- TXMD 0.02
- Stochastic Oscillator
- GXAI 9.23
- TXMD 49.30
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.